Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ove, Roger
NCT05846646: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC	Terminated	2	6	US	IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR	ImmuneSensor Therapeutics Inc.	Oligometastatic Disease	09/24	09/24
NCT05846659: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies	Terminated	2	16	US	IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR	ImmuneSensor Therapeutics Inc.	Oligoprogressive	11/24	11/24
NCT03972527: Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients	Completed	N/A	85	US	Photobiomodulation, low-level laser therapy, Routine Oral Care and Analgesia, Pain medication, oral rinses	MuReva Phototherapy Inc.	Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer	06/24	07/24